(MedPage Today) — The FDA has approved a new sublingual tablet formulation of the opioid addiction drug buprenorphine-naloxone (Zubsolv), drugmaker Orexo U.S. announced. (Source: MedPage Today Psychiatry)
MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.